Loading
A phase 2 trial of Ropeginterferon alfa-2b in myeloproliferative neoplasms, run by PharmaEssentia, active and no longer recruiting.
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU is a phase 2 interventional study registered as NCT05485948 by PharmaEssentia, with 49 participants enrolled, started 2021-10-08 and due to reach its primary completion in 2022-09-07. Interventions recorded: Ropeginterferon alfa-2b.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PharmaEssentia, Ropeginterferon alfa-2b, Polycythaemia vera (PV), Cytokines & engineered cytokines and the tag pipeline.
Shares PharmaEssentia, Ropeginterferon alfa-2b, Polycythaemia vera (PV), Cytokines & engineered cytokines and the tag pipeline.
Shares PharmaEssentia, Ropeginterferon alfa-2b, Cytokines & engineered cytokines, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares PharmaEssentia, Ropeginterferon alfa-2b, Cytokines & engineered cytokines, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares PharmaEssentia, Ropeginterferon alfa-2b, Cytokines & engineered cytokines, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/